September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between pharmaceutical giant Pfizer (NYSE: PFE) and the U.S. government has sparked a "relief rally" for some major players, the broader market remains
Washington D.C. – September 30, 2025 – Shares of Agilent Technologies (NYSE: A) experienced a significant upward movement today, closing strong amidst breaking news of a landmark drug-pricing agreement between the White House and pharmaceutical giant Pfizer (NYSE: PFE). This surge, echoing similar positive movements for other life sciences companies like
As of September 30, 2025, the financial markets are grappling with the implications of a landmark drug-pricing agreement between the White House and pharmaceutical giant Pfizer (NYSE: PFE), a move signaling a broader governmental push to significantly lower prescription drug costs. While such developments typically send ripples across the entire
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth.
This has capped the upside for healthcare stocks lately as the industry’s flat return over the past six months has trailed the S&P 500’s 18.3% gain.
Hitting a new 52-week low can be a pivotal moment for any stock.
These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
Shares of life sciences company Revvity (NYSE:RVTY)
fell 5.1% in the afternoon session after several analyst firms lowered their price targets on the stock, pushing shares to a 52-week low. The negative sentiment comes despite a recent second-quarter earnings report where Revvity surpassed analyst expectations for both revenue and earnings per share. However, firms including Stifel, Raymond James, and Jefferies cut their price targets. Analysts cited ongoing challenges in China, including pressures from the ImmunoDx market, reimbursement difficulties, and the impact of drug-related group policies on the company's financial outlook. The stock's fall to a new 52-week low of $85.01 reflects investor concerns that these specific market headwinds are outweighing the recent positive earnings results.
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Wednesday as we examine the latest happenings in today's session.
Looking for the S&P500 stocks that are experiencing notable gaps on Wednesday? Find out which stocks are gapping up and gapping down in the S&P500 index during today's session.
Shares of life sciences company Revvity (NYSE:RVTY)
fell 3.1% in the afternoon session after the major indices continued to retreat (Nasdaq -1.5%, S&P 500 -1.2%) amid profit-taking and renewed concerns about tariffs.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.
A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested that with inflation risks moderating and unemployment remaining low, the Federal Reserve might consider a shift in its monetary policy stance, including potential interest rate cuts. This outlook eased market concerns about prolonged high interest rates and their impact on economic growth. The prospect of lower borrowing costs bolstered investor confidence, particularly in sectors that have lagged, leading to a broad rally across the market.
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth-oriented sectors like healthcare, as they reduce the cost of borrowing for research and innovation and increase the present value of future earnings.
Life sciences company Revvity (NYSE:RVTY) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.1% year on year to $720.3 million. The company expects the full year’s revenue to be around $2.86 billion, close to analysts’ estimates. Its non-GAAP profit of $1.18 per share was 3.4% above analysts’ consensus estimates.
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Avantor (NYSE: AVTR) shares have recently experienced a significant and sustained plunge, hitting a 52-week low and reflecting a challenging period for the life sciences company. This sharp decline is a direct consequence of both a widespread market sell-off and a confluence of company-specific issues, sending ripples of concern through
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets.
But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
